drugset / Trial / NCT05004324
Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This clinical trial study is two-stage, multi-center, randomized, double-blind, placebo controlled, phase 3 clinical trial to evaluate the efficacy and safety of FURESTEM-AD Inj. for moderate to severe chronic atopic dermatitis.
Timeline
- Start
- 2021-06-29
- Primary completion
- 2023-01
- Completion
- 2023-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FURESTEM-AD® | Unknown | 1.5 ml | Other |
| Subject | FURESTEM-AD® | Unknown | 5e+07 cells | Other |